Drugs / EuTCV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03956524 | Mar → Aug 2019 | typhoid fever | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04830371 | Sep 2020 → Mar 2021 | typhoid fever | EuBiologics Co.,Ltd | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EuTCV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04830371 ↗ |
| Known as | Vi-CRM197 | “Here, we assessed the safety, tolerability, and immunogenicity of a TCV, Vi-CRM197, termed EuTCV, in an open-label clinical phase I study in healthy Filipino adults.” PMID 33849723 ↗ Apr 2021 |
| Route | Intramuscular | “Single dose of EuTCV will be administered intramuscularly” NCT03956524 ↗ |